SCHEMBL992202

SCHEMBL992202

COc1ccc(NC(=O)O)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.73
NPC1 O15118 6/20 0.73
SMN1; SMN2 Q16637 5/20 0.73
TP53 P04637 1/20 0.66
ALOX15 P16050 1/20 0.66
TGM2 P21980 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
MAPT P10636 3/20 0.59
ALDH1A1 P00352 2/20 0.59
KDM4E B2RXH2 2/20 0.59
CYP1A2 P05177 2/20 0.59
CYP2C19 P33261 2/20 0.59
GAA P10253 1/20 0.59
HTT P42858 1/20 0.59
MEN1 O00255 1/20 0.59
KMT2A Q03164 1/20 0.59
SAE1 Q9UBE0 1/20 0.59
UBA2 Q9UBT2 1/20 0.59
CYP2D6 P10635 1/20 0.59
CYP2C9 P11712 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methane SCHEMBL2365682 0.98 RAB9A (0.70) RAB9ANPC1SMN1; SMN2TP53ALOX15
SCHEMBL11394952 0.94 NPC1 (0.66) RAB9ANPC1SMN1; SMN2TP53ALOX15
SCHEMBL3975157 0.94 RAB9A (0.66) RAB9ANPC1SMN1; SMN2TP53ALOX15
SCHEMBL29135461 0.89 SAE1 (0.78) RAB9ANPC1SMN1; SMN2TP53ALOX15
SCHEMBL7454467 0.85 KMT2A (0.72) RAB9ANPC1SMN1; SMN2L3MBTL1MAPT
SCHEMBL6396790 0.84 RAB9A (0.76) RAB9ANPC1SMN1; SMN2TP53ALOX15
SCHEMBL11092496 0.84 RAB9A (1.00) RAB9ANPC1SMN1; SMN2TP53ALOX15
Hydrochloric Acid SCHEMBL9038264 0.83 KMT2A (0.70) RAB9ANPC1SMN1; SMN2L3MBTL1MAPT
SCHEMBL11721311 0.83 RAB9A (0.68) RAB9ANPC1SMN1; SMN2TP53ALOX15
SCHEMBL4058023 0.83 NPC1 (0.56) RAB9ANPC1SMN1; SMN2TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3630717-B1 A PROCESS FOR THE SYNTHESIS OF AROMATIC CARBAMATES COUNCIL SCIENT IND RES (IN) 2022-02-09 EP claimed
US-10703714-B2 Process for the synthesis of aromatic carbamates COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2020-07-07 US claimed
US-20200148631-A1 A PROCESS FOR THE SYNTHESIS OF AROMATIC CARBAMATES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2020-05-14 US claimed
EP-3630717-A1 A PROCESS FOR THE SYNTHESIS OF AROMATIC CARBAMATES Council of Scientific and Industrial Research (IN) 2020-04-08 EP claimed
WO-2018216036-A1 A PROCESS FOR THE SYNTHESIS OF AROMATIC CARBAMATES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2018-11-29 WO claimed
CN-106046100-A 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and the use thereof for treating diseases 拜耳知识产权有限责任公司 2016-10-26 CN claimed
EP-2186506-B1 Teeth cleaning compound containing menthol with reduced bitter sensation SYMRISE AG (DE) 2015-09-30 EP claimed
EP-2456783-B1 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ETHINYLPHENYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES BAYER IP GMBH (DE) 2015-08-19 EP claimed
EP-1879877-B1 ANTIMICROBIAL AGENTS RANBAXY LAB LTD (IN) 2013-01-02 EP claimed
EP-2456783-A2 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ETHINYLPHENYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES Bayer Pharma Aktiengesellschaft (DE) 2012-05-30 EP claimed
US-20090082399-A1 Carbamate derivatives as positive allosteric modulators of metabotropic glutamate receptors ADDEX PHARMA SA (CH) 2009-03-26 US claimed
EP-1893200-A2 CARBAMATE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2008-03-05 EP claimed
EP-1799673-A1 PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS Memory Pharmaceuticals Corporation (US) 2007-06-27 EP claimed
EP-1594835-A4 METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES AUSPEX PHARMACEUTICALS INC (US) 2007-05-02 EP claimed
WO-2006123244-A2 CARBAMATE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2006-11-23 WO claimed
US-20060173199-A1 Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses HONG BORCHERNG 2006-08-03 US claimed
US-20060154960-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2006-07-13 US claimed
WO-2006044528-A1 PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2006-04-27 WO claimed
EP-1594835-A2 METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES Auspex Pharmaceuticals, Inc. (US) 2005-11-16 EP claimed
WO-2004064745-A2 METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES AUSPEX PHARMACEUTICALS, INC. (US) 2004-08-05 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082399-A1 Carbamate derivatives as positive allosteric modulators of metabotropic glutamate receptors GRM5, GRIK5, GRM1 RAB9A 723/4885NPC1 2603/4885SMN1; SMN2 3376/4885
US-20200148631-A1 A PROCESS FOR THE SYNTHESIS OF AROMATIC CARBAMATES TYR, DDC, ALK RAB9A 3127/4885NPC1 4157/4885SMN1; SMN2 4574/4885
US-10703714-B2 Process for the synthesis of aromatic carbamates ALK, DDC, TYR RAB9A 3122/4885NPC1 4118/4885SMN1; SMN2 4611/4885
US-20060154960-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE12 RAB9A 1437/4885NPC1 4728/4885SMN1; SMN2 1922/4885
US-20060173199-A1 Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses LSS, DHPS, CYP51A1 RAB9A 1188/4885NPC1 2068/4885SMN1; SMN2 4543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.